

## USP Workshop on Computer Modeling – In vitro and In vivo Studies October 23–25, 2017 USP Meetings Center, Rockville, MD USA

Final Agenda

## DAY ONE: Monday, October 23, 2017

8:00 – 8:30 a.m.	Registration & Coffee
8:30 a.m.	Welcome
8:30 – 9:00 a.m.	<b>USP Revision Process</b> John Mauger, Ph.D., USP General Chapters-Dosage Forms Expert Committee, Professor, Pharmaceutical Chemistry, University of Utah
9:00 – 9:30 a.m.	Bridging In silico with In vivo for Better Drug Development Alan Parr, Ph.D., USP Compounding Expert Committee, Managing Member, BioCeutics, LLC
9:30 – 10:00 a.m.	<b>Modeling and Measurement Uncertainty</b> Jane Weitzel, USP General Chapters-Statistics Expert Committee, Independent Consultant
10:00 – 10:30 a.m.	Morning Break
10:30 – 11:00 a.m.	Applications of Modeling in Quantitative Biopharmaceutics to Bridge Formulation and Clinical Performance David Good, Ph.D., Senior Research Investigator, Bristol-Meyers Squibb
11:00 – 11:30 a.m.	Predicting Product Performance: Integrated In vitro Dissolution and In vivo Absorption Modeling David C. Sperry, Ph.D., <i>Research Advisor, Eli Lilly</i> & Company
11:30 a.m. – 12:00 p.m.	Q&A
12:00 – 1:00 p.m.	Lunch
1:00 – 1:30 p.m.	<b>Dissolving a Drug In vitro and In vivo via In silico – A Case Study</b> Hu Wang, Ph.D., USP Expert Panel Member-Use of Enzymes in the Dissolution Testing of Gelatin Capsules, Senior Scientist, Merck & Co.
1:30 – 2:00 p.m.	Translating In vitro Data to In vivo Predictions – Is PBPK Modeling the Missing Link? Edmund Kostewicz, Ph.D., Senior Scientist, Goethe University, Germany
2:00 – 2:30 p.m.	Afternoon Break



2:30 – 3:00 p.m.	Mechanistic Oral Absorption & PBPK Modelling to Understand Formulation Behavior & Preclinical Pharmacokinetics Devendra Pade, Ph.D., Senior Research Scientist, Simcyp Limited (a Certara Company), Blades Enterprise Center, Sheffield, UK
3:00 – 3:30 p.m.	Prediction of Formulation Bioperformance and Bioequivalence by Incorporating Dissolution Data in PBPK Models Amitava Mitra, Ph.D., <i>Clinical Development, Sandoz, Inc.</i>
3:30 – 4:00 p.m.	Q&A
4:00 – 5:00 p.m.	Networking Reception

## DAY TWO: Tuesday, October 24, 2017

8:00 – 8:30 a.m.	Registration & Coffee
8:30 – 9:00 a.m.	<b>Oral IVIVC Simulation</b> James E. Polli, Ph.D., <i>Professor, University of Maryland School of</i> <i>Pharmacy</i>
9:00 – 9:30 a.m.	Clinical Relevant Product Specifications: Understanding In vitro and In vivo Data Using In silico Approaches Raimar Löbenberg, Ph.D., USP BDSHM and NBDS - General Chapters Joint Subcommittee, Professor, Pharmacy & Pharmaceutical Studies, University of Alberta, Canada
9:30 – 10:00 a.m.	In vitro Evaluation of Dissolution and PBPK Modeling to Understand the Impact of Absorption of High Dose Low Solubility Drugs from the Lower Intestine Maria Vertzoni, Ph.D., <i>Faculty of Pharmacy, University of Athens, Greece</i>
10:00 – 10:30 a.m.	Morning Break
10:30 – 11:00 a.m.	<b>Comparison Between Mechanistic Dissolution Modeling and Experimental Observations of Dissolution of Pharmaceuticals</b> Susan Ewing, <i>Senior Scientist, Biopharmaceutics Group, Pfizer, Inc.</i>
11:00 – 11:30 a.m.	In silico Simulations of Intrinsic Dissolution Humberto Ferraz, Ph.D., Professor, Department of Pharmacy, University of Sao Paulo, Brazil
11:30 a.m. – 12:00 p.m.	Q&A
12:00 – 12:50 p.m.	Lunch
12:50 – 1:00 p.m.	Workshop Evaluation



1:00 – 1:30 p.m.	Simulation and Comparison of Hydrodynamics in Compendial Dissolution Apparatuses Using Computational Fluid Dynamics (CFD) Deirdre M. D'Arcy, Ph.D., Assistant Professor, Trinity College of Dublin, School of Pharmacy and Pharmaceutical Studies
1:30 – 2:00 p.m.	A Case for Bioequivalence Knowledge Creation Ene Ette, MBA, Ph.D., President, Anoixis Corporation
2:00 – 2:30 p.m.	Physiologically Base Pharmacokinetic and Absorption Modeling and Simulation – Cases Studies Xinyuan (Susie) Zhang, Ph.D., <i>Pharmacologist, CDER, U.S. Food and</i> <i>Drug Administration</i>
2:30 – 3:00 p.m.	Afternoon Break
3:00 – 3:30 p.m.	Development of a Multivariate Model for Simulation of Cascade Impactor Data Dennis Sandell, Ph.D., <i>Director, S5 Consulting</i>
3:30 – 4:00 p.m.	Predicting Deposition and Absorption Rate for Orally Inhaled Products Based on Dissolution Data and a PK Simulation Model Guenther Hochhaus, Ph.D., <i>Professor, Pharmaceutics, University of</i> <i>Florida</i>
4:00 – 4:30 p.m.	Combining in vitro Mouth-Throat Deposition Measurements, Cascade Impactor Data and Computational Fluid Dynamics (CFD) Simulations Herbert Wachtel, Ph.D., Senior Principal Scientist, Boehringer Ingelheim, Germany
4:30 – 5:00 p.m.	Q&A

## DAY THREE: Wednesday, October 25, 2017

8:00 – 8:30 a.m.	Registration & Coffee
8:30 – 9:00 a.m.	In Silico Modeling and Simulations to Support Development and Bioequivalence Assessment of Generic Drug Product Jasmina Novakovic, Ph.D., Scientific Leader, Apotex Inc.
9:00 – 9:30 a.m.	Using In silico Simulation to Aid Development of an In-vivo Assay for Vaccine Potency Assessment Ryan Yamagata, USP Bioassay General Chapter Expert Panel, Principal Statistician, GSK
9:30 – 10:00 a.m.	Challenges in Physiologically Based Pharmacokinetic Modeling for the Prediction of In vivo Performance After Oral Administration Nikoletta Fotaki, Ph.D., <i>Reader (Assoc/Full Professor) in Pharmaceutics,</i> Department of Pharmacy and Pharmacology, University of Bath
10:00 – 10:30 a.m.	Morning Break



10:30 – 11:00 a.m.	Population-Based PBPK and IVIV_E of Dissolution and Precipitation: Current Status and What Next? David Turner, Ph.D., <i>Principal Scientist, Simcyp Limited (a Certara Company)</i>
11:00 – 11:30 a.m.	Advances and Challenges of Modeling and Simulation Studies in Regulatory Submissions Maziar Kakhi, Ph.D., Staff Fellow, U.S. Food & Drug Administration
11:30 a.m. – 12:00 p.m.	Computer Modeling and Biphasic Dissolution Jim Mullin, Principal Scientist, Simulations-Plus, Inc.
12:00 – 12:30 p.m.	Q&A
12:30 – 12:35 p.m.	Workshop Report / Closing Remarks Margareth Marques, Ph.D., USP Principal Scientific Liaison, General Chapters
12:35 p.m.	Workshop Concludes Boxed Lunches will be available